Alpha Teknova Earnings Call Transcripts
Fiscal Year 2026
-
Record Q2 2026 revenue grew 18% year-over-year, driven by broad-based demand except for cell and gene therapy. Raised 2026 revenue guidance to $45–$47M, launched Build-Tek AI configurator, and saw improved profitability and cash flow. Commercial investments and biotech funding are expected to drive future growth.
-
Q1 2026 saw 13% revenue growth, led by an 85% surge in Clinical Solutions and improved gross margin. Investments in commercial capabilities and automation are expected to drive double-digit growth in 2027, with positive adjusted EBITDA targeted by year-end 2027.
-
Revenue reached $40.5 million in 2025 with strong growth in both catalog and custom GMP products. Investments in sales, marketing, and technology, along with a new GMP facility, position the business for profitability by 2027. Clinical Solutions and Lab Essentials segments drive future upside as therapies advance through clinical stages.
Fiscal Year 2025
-
Revenue grew 7% in 2025 with improved gross margins and reduced losses. Investments in commercial capabilities and a recovering biotech market are expected to drive future growth, with positive adjusted EBITDA targeted by end of 2027.
-
Q3 2025 saw 9% revenue growth and improved gross margins, led by strong Lab Essentials sales, while Clinical Solutions revenue declined. The outlook remains cautious for biopharma custom products, but double-digit growth continues in other segments. Guidance for 2025 revenue is $39–$42 million, with no need for additional capital.
-
Q2 2025 saw 7% revenue growth, strong catalog sales, and improved gross margin to 38.7%. Clinical Solutions revenue rose 32% YoY, while guidance for 2025 was reiterated at $39–$42 million. Operational efficiencies and a growing customer base support long-term growth.
-
Custom and catalog reagent provider leverages recent infrastructure investments to scale rapidly, targeting 20%-25% growth and higher margins. Strong customer retention, fast turnaround, and new partnerships position the business for long-term profitability and expansion.
-
Q1 2025 revenue grew 5% year-over-year to $9.8M, with strong catalog product growth and improved gross margin. Guidance for 2025 was reiterated, expecting 7% revenue growth and continued margin improvement, while a new collaboration with Pluristyx expands the product portfolio.
Fiscal Year 2024
-
2024 saw revenue growth, improved cash flow, and reduced expenses, with strong gains in clinical and biopharma segments. 2025 guidance anticipates 7% revenue growth, margin expansion, and continued cost discipline amid cautious customer spending and macro uncertainty.
-
The company has stabilized after a challenging period, with strong growth in its catalog business and expanding clinical customer base. New offerings like Express-Tek and RUO+ are gaining traction, and cost reductions have positioned the business for profitability. Long-term growth targets remain ambitious, with a focus on innovation and operational efficiency.
-
Q3 2024 saw 17% revenue growth year-over-year, driven by biopharma custom product sales and increased clinical customer count. Gross margin was impacted by a $2.8M inventory write-down, but cost controls led to the lowest free cash outflow in three years. 2024 revenue guidance is flat, with liquidity sufficient to reach profitability.
-
A custom reagents provider is leveraging a new GMP-certified facility, proprietary product launches, and a focused commercial strategy to drive growth, especially in cell and gene therapy. Financial targets include breakeven at $50–$55M revenue, with recent funding expected to support the path to profitability.
-
Q2 2024 revenue was $9.6M, down 17% year-over-year but up 3% sequentially, with underlying growth of 9% excluding a large prior-year order. New product launches and increased clinical customer count support a positive outlook, and a $15.4M capital raise strengthens liquidity. Guidance for 2024 is reaffirmed, with double-digit growth expected in the second half.